@kingsioppn.bsky.socialEarlier this year, King’s researchers identified a previously unknown form of cell death in Alzheimer's, called karyoptosis. 🧠
The discovery could open up new avenues for future treatment development.
🔗 Read more: www.kcl.ac.uk/news/new-mec...
@alzheimersresearchuk.org
#AlzheimersResearch
@keck.usc.eduNew in Nature Communications: @uscloni.bsky.social researchers introduce CCSI, comparing 7-Tesla MRI blood flow to cortical cell density across 360 brain regions. Alignment was strongest in visual and sensorimotor cortex. #AlzheimersResearch https://bit.ly/4yNh8Ns
@resist47.newsTrump administration funding cuts may force the shutdown of a Pittsburgh Alzheimer's study, impacting 600 aging participants before they receive cognitive test...
resist47.news — your resistance news source.
#resist47 #AlzheimersResearch #TrumpFundingCuts #PittsburghHealth #ScientificResearch
@kingsioppn.bsky.socialEarlier identification could give Alzheimer’s treatments a better chance to work. 🧠
King’s researchers found that being biologically older than your actual age was linked to greater dementia risk and earlier onset.
@nihrmaudsleybrc.bsky.social
@apcmicrobiomeirel.bsky.social@anatneuroucc.bsky.social @ucla.edu @teagasc.bsky.social
@kingsioppn.bsky.socialEarlier this year, King's researchers found they could tackle one aspect of the early stages of Alzheimer's disease using an experimental cancer drug 💊 in the lab.
#AlzheimersResearch #WorldAlzheimersMonth
Find out more ⬇️
www.kcl.ac.uk/news/early-a...
@lnvh.nlMeet Luisa Epifani, the first of our two 2025–2026 AWiB Grant laureates. Her PhD research explores why women face a higher risk of Alzheimer's disease, particularly after menopause. #AlzheimersResearch #BrainHealth #LNVH #AWiB
@keck.usc.eduA blood-based screening algorithm is a clinical trial tool that flags Alzheimer's risk using plasma biomarkers, cutting unnecessary PET scans from over 70% to 31% in the AHEAD 3-45 study. Published in Alzheimer's & Dementia. #AlzheimersResearch https://bit.ly/4xeUPyG
@rpeptide.bsky.socialCould targeting CD22 both reduce neuroinflammation and clear Aβ in Alzheimer's Disease?
Research demonstrates a dual mechanism for suciraslimab in microglia, using rPeptide's Beta-Amyloid (1-42) HFIP (A-1163-1) and Fluorescein Aβ (1-42) (A-1119-1). 🧠
@doctoradda.bsky.socialLast week’s AHEAD Study webinar gave me a chance to reflect on 25+ years of Alzheimer’s clinical trials at Rush.
Click: lnkd.in/p/g8c7xsaK
#ClinicalTrials #AlzheimersResearch #AHEADStudy #Rush #RADCClinicalTrials
@chemcenterbio.bsky.socialIs J147 The Most Potent Brain Compound Ever Created?
Preclinical research shows J147 rescues neurodegenerative biomarkers with ninety times curcumin potency in animals only.
#J147 #AlzheimersResearch #Neuroscience #Biochemistry #preclinicalresearch
@the-ccad.bsky.social"I was really navigating on my own for a while."
Early in her career, Dr. Tansey had to learn the grant process through experience. That journey shaped her belief in the power of mentorship.
🎙️ Full episode coming 9/25
@the-ccad.bsky.socialResearch is full of challenges, but don't let them define what's possible.
"It may not be easy, but it's not impossible."
More wisdom from Dr. Malu Tansey on The CCAD Exchange is coming September 25.
#TheCCADExchange #EarlyCareerResearchers #AlzheimersResearch #Podcast
@the-ccad.bsky.socialYour environment matters but the people matter even more. In this preview from The CCAD Exchange, Malu Tansey explains why finding mentors and colleagues who believe in you can make all the difference.
🎙️ Full episode coming 9/25
#TheCCADExchange #AlzheimersResearch #Neuroscience #ResearchCommunity